Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
Novel Therapeutic Strategies for Neuro-Oncology
share announcement

Novel Therapeutic Strategies for Neuro-Oncology

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Neuro-Oncology".

Deadline for manuscript submissions: closed (15 May 2023) | Viewed by 4971

Special Issue Editors

Dr. Christian F. Freyschlag

E-Mail Website
Guest Editor
Associate Professor, Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria
Interests: neuro-oncological surgery; intraoperative tumor visualization; cell–cell communication
Special Issues, Collections and Topics in MDPI journals
Dr. Astrid E. Grams

E-Mail Website
Guest Editor
Associate Professor, Department of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria
Interests: metabolic imaging; noninvasive tumor profiling; interventional neuroradiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Current Oncology Special Issue on Novel Therapeutic Strategies for Neuro-Oncology. Within our fast-growing scientific field, we would like to endorse researchers in search of visionary and brave endeavors to submit their work, including specialties of clinical, translational and basic research in neuro-oncology. We welcome manuscripts concerning surgical excellence, promising treatment targets, prognostic and predictive markers, neuroimaging and combinations thereof, including big data research.

With this Special Issue, we aim to promote novel and visionary treatment strategies carried out in clinical pilot projects and basic and translational research. We endorse all specialists involved in neuro-oncology to submit manuscripts. Surgical technique and visualization, imaging (both MR and PET) as well as radiotherapy and medical treatment will be featured in this Special Issue, welcoming original research articles and reviews.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Cancers.

Dr. Christian F. Freyschlag
Dr. Astrid E. Grams
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuro-oncology
  • neurosurgery
  • radiation therapy
  • neuroimaging
  • glioma
  • glioblastoma
  • brain metastasis
  • translational research
  • cell communication
  • treatment resistance
  • tumor metabolomics
  • combined treatment
  • low-grade gliomas
  • tumor-treating fields

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 292 KiB  
Article
The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
by Brandon Kaye, Assad Ali, Raphael Augusto Correa Bastianon Santiago, Bilal Ibrahim, Julio Isidor, Hany Awad, Mohammadmahdi Sabahi, Michal Obrzut, Badih Adada, Surabhi Ranjan and Hamid Borghei-Razavi
Curr. Oncol. 2023, 30(5), 4946-4956; https://doi.org/10.3390/curroncol30050373 - 12 May 2023
Cited by 2 | Viewed by 1901
Abstract
Introduction: Glioblastoma (GBM) patients have a 20–30 incidence of venous thromboembolic events. EGFR is a widely used prognostic marker for many cancers. Recent lung cancer studies have described relationships between EGFR amplification and an increased incidence of thromboembolic complications. We aim to explore [...] Read more.
Introduction: Glioblastoma (GBM) patients have a 20–30 incidence of venous thromboembolic events. EGFR is a widely used prognostic marker for many cancers. Recent lung cancer studies have described relationships between EGFR amplification and an increased incidence of thromboembolic complications. We aim to explore this relationship in glioblastoma patients. Methods: Two hundred ninety-three consecutive patients with IDH wild-type GBM were included in the analysis. The amplification status of EGFR was measured using fluorescence in situ hybridization (FISH). Centromere 7 (CEP7) expression was recorded to calculate the EGFR-to-CEP7 ratio. All data were collected retrospectively through chart review. Molecular data were obtained through the surgical pathology report at the time of biopsy. Results: There were 112 subjects who were EGFR-amplified (38.2%) and 181 who were non-amplified (61.8%). EGFR amplification status was not significantly correlated with VTE risk overall (p = 0.2001). There was no statistically significant association between VTE and EGFR status after controlling for Bevacizumab therapy (p = 0.1626). EGFR non-amplified status was associated with an increased VTE risk in subjects greater than 60 years of age (p = 0.048). Conclusions: There was no significant difference in occurrence of VTE in patients with glioblastoma, regardless of EGFR amplification status. Patients older than 60 years of age with EGFR amplification experienced a lower rate of VTE, contrary to some reports on non-small-cell lung cancer linking EGFR amplification to VTE risk. Full article
(This article belongs to the Special Issue Novel Therapeutic Strategies for Neuro-Oncology)

Other

Jump to: Research

10 pages, 501 KiB  
Systematic Review
Temozolomide Chronotherapy in Glioma: A Systematic Review
by Jason L. Jia, Bader Alshamsan and Terry L. Ng
Curr. Oncol. 2023, 30(2), 1893-1902; https://doi.org/10.3390/curroncol30020147 - 04 Feb 2023
Cited by 9 | Viewed by 2647
Abstract
Outcomes for patients with high-grade glioma remain poor. Temozolomide (TMZ) is the only drug approved for first-line treatment of glioblastoma multiforme, the most aggressive form of glioma. Chronotherapy highlights the potential benefit of timed TMZ administration. This is based on pre-clinical studies of [...] Read more.
Outcomes for patients with high-grade glioma remain poor. Temozolomide (TMZ) is the only drug approved for first-line treatment of glioblastoma multiforme, the most aggressive form of glioma. Chronotherapy highlights the potential benefit of timed TMZ administration. This is based on pre-clinical studies of enhanced TMZ-induced glioma cytotoxicity dependent on circadian, oscillating expression of key genes involved in apoptosis, DNA damage repair, and cell-cycle mediated cell death. The current systematic review’s primary aim was to evaluate the efficacy and toxicity of TMZ chronotherapy. A systemic review of literature following PRISMA guidelines looking at clinical outcomes on TMZ chronotherapy on gliomas was performed. The search in the English language included three databases (PubMed, EMBASE, and Cochrane) and five conferences from 1946 to April 2022. Two independent reviewers undertook screening, data extraction, and risk-of-bias assessment. A descriptive analysis was conducted due to limited data. Of the 269 articles screened, two unique studies were eligible and underwent abstraction for survival and toxicity findings. Both studies—one a retrospective cohort study (n = 166) and the other a prospective randomized feasibility study (n = 35)—were conducted by the same academic group and suggested a trend for improved overall survival, but possibly increased toxicity when TMZ was administered in the morning (vs. evening). There was limited evidence suggesting possible therapeutic value from administering TMZ in the morning, which may be consistent with the pre-clinical observations of the importance of the timing of TMZ administration in vitro. Larger, pragmatic, prospective randomized controlled trials are needed to ascertain the value of TMZ chronotherapy to provide optimized and equitable care for this population. Full article
(This article belongs to the Special Issue Novel Therapeutic Strategies for Neuro-Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop